About Us

Cosmic was setup by a group of technocrats, academics, industrialists with more than 75 years of combined experience in Pharmaceutical science and emerging technologies.

Management Team

G Sudarsana Reddy

G Sudarsana Reddy

CEO and MD

Mr. Reddy has over 25 years of rich experience in pharmaceutical industry, and specializes in analytical Method development, Chiral Purifications and Impurity isolation. In 1987 he started his career at Dr Reddy’s as an analytical chemist and spent around 17 years with progressively increasing responsibility. At Reddy’s he was involved in developing analytical methods (HPLC & GC) for active pharmaceutical entities (API’S) and key intermediates. He has several publications in the field of impurity isolation and characterization. Subsequently he associated with GVKBIO, AVRA LABORATORIES and his last assignment was with Sai Life Sciences.

Born in Guntur district of Andhra Pradesh, Mr. Sudarsana Reddy completed his early education locally and moved to Hyderabad to complete his M.Sc Tech in pharmaceutical chemistry from Birla Institute of Technology.

Dr. GR Madhavan

Dr. GR Madhavan

CSO

Dr. Madhavan has over 23 years of experience in CRO industries like GVKbio, Jubilant biosys, Chembiotek and Eurofins-Advinus, and medicinal chemistry fields in drug discovery like Dr.Reddy’s Labs, Connexios lifesciences. Contributed for several drugs in clinical trials in past experience and headed the medicinal chemistry department, has >25 patents(PCT &US) and 10 publications. (Osmania University, organic chemistry).

Dr. Aman Iqbal

Dr. Aman Iqbal

Head, Corporate Development

Aman is a technology and healthcare visionary, an idea machine and a sharp-executer. In his professional career spanning over a decade, he has had diverse working experience from academia, to mid-cap biotech to public-private research organization funded by all major Pharma companies and numerous healthcare based startups. His passion for pushing the boundaries of human understanding of science and merging disciplines in the quest of finding solutions to some of the most challenging problems faced by the healthcare industry has won him many accolades including Primer Minister’s Top 40 under 40 emerging entrepreneurs of Canada to NextFounders, and member of the Executive Club of Canada.

He has co-founded DigiMed Inc. (early forays into digital medicine), Cosmic Discoveries (Contract biotech R&D firm using machine learning for streamlining Pharmaceutical API R&D), Ampkyne (repurposing a Phase-1 metabolic drug for mitochondrial diseases , GreyWolf Animal health (a next generation animal health company), Proteorex therapeutics (drugging the undruggable genome), IQGEN (Healthcare Corporation on a mission to create Unicorns in Asia). Besides the successes he is also proud of the failures that helped him shape into a ‘war-hardened’ entrepreneur, mentor and investor.

Aman sits on the board of RadiomicsAI (winner of world’s top 20 companies in the Medical AI space by Red Herring group).

Aman got his PhD in Chemical Biology at the ripe age of 24 from University of Oxford where he was a Wellcome trust fellow making him the youngest PhD in Chemistry from South Asia.

Laurent Balenci

Laurent Balenci

Manager, Business Development North America

Laurent has over 15 years of experience in the life sciences industry with roles of increasing responsibility in R&D, business development, program management and operations. Serial entrepreneur with over 5-year C-level executive experience (Ketogen, RFE, Forward Vue, Kondor Health), Laurent has helped secure ~$4.5M in non-dilutive and ~$25+M in dilutive funding, as well as has raised company valuation up to $40M. Laurent is an Entrepreneur-in-Residence/scout for two angel groups for which he performs business, financial, scientific, strategic planning due diligence on a regular basis and provide recommendations for investment. Laurent has founded his own early-stage management consulting boutique to help entrepreneurs with business development (pitch deck, technology one-pager, executive summary and promotional/marketing materials, target list), strategic planning (preclinical, clinical, CMC, regulatory), due diligence materials, grant applications, start-to-end outsourcing work. Laurent worked as a Commercialization Manager at the Innovations and Partnerships Office of the University of Toronto, where he helped academics with business and project planning, partnering, go-to-market strategy, market research, competitive landscape, and company creation. Laurent holds a PhD in Neurobiology from Joseph Fourier University (France), during which he helped Animage, a young start-up company, becoming the main imaging platform for the South Hospital Network in Lyon. He also established a partnership with Erytech Pharma to design and build an ex-vivo brain tumor biopsy/extracting system. He pursued his post-doctoral training in stem cell research at the University of Toronto, where he received the prestigious post-doctoral McEwen award.

Board of Directors

G Sudarsana Reddy

G Sudarsana Reddy

CEO and MD

Mr. Reddy has over 25 years of rich experience in pharmaceutical industry, and specializes in analytical Method development, Chiral Purifications and Impurity isolation. In 1987 he started his career at Dr Reddy’s as an analytical chemist and spent around 17 years with progressively increasing responsibility. At Reddy’s he was involved in developing analytical methods (HPLC & GC) for active pharmaceutical entities (API’S) and key intermediates. He has several publications in the field of impurity isolation and characterization. Subsequently he associated with GVKBIO, AVRA LABORATORIES and his last assignment was with Sai Life Sciences.

Born in Guntur district of Andhra Pradesh, Mr. Sudarsana Reddy completed his early education locally and moved to Hyderabad to complete his M.Sc Tech in pharmaceutical chemistry from Birla Institute of Technology.

Dr. Vinod Hegde

Dr. Vinod Hegde

Investor and Director

Dr. Vinod Hegde completed M.Sc. from Karnataka University, worked briefly at CIBA-GEIGY Research Center in Mumbai and then left for USA to complete his doctoral degree at Stevens Institute of Technology. In 1985, he started his career at Schering-Plough Research Institute as natural product chemist, assumed increasing responsibilities and in early 2000, he moved to process development helping process chemistry in analytical issues, impurity management and separations. He was also involved in resolving FDA consent decree issue and managed impurity isolation and characterization for all departments including Discovery and consumer products. In 2012 he joined SAI Life Science in Hyderabad (India) as Vice President/Consultant for Analytical Research & Development. At SAI, he consolidated two analytical groups, designed a new AR&D facility, increased efficiency and modernized to meet western standards. Dr Hegde has extensive knowledge in all aspects of analytical chemistry and proficient in FDA, ICH EMEA guidelines. He had discovered over 100 new natural products active in several therapy areas and has published over 75 publications in prestigious journals. He is author of 11 patents and has written chapters in scientific books. He had collaboration with many academic labs in US as well as China, Russia, Brazil, Costa Rica and India. He also holds an MBA from Rutgers University.

Dr. Vinod Hegde

G Subbareddy

Investor and Director

G Subbareddy is a serial entrepreneur and a major investor in Cosmic with over 30 years of building businesses in chemicals, real-estate and education space. Mr. Subbareddy brings forth strategic and financial advisory expertise to Cosmic and continues to fund the company as it builds it hard asset capabilities.

Advisory Board

Dr. Vinod Hegde

William Sutton

Business Development Advisor

Bill, a chemical engineer, and health care business executive, provides clients the expertise to address complex business strategies and manufacturing issues. Bill began consulting with Booz Allen in their Pharmaceutical and Biotechnology Practice; later he founded the Quantic Group, a pharmaceutical consulting organization; and served as Senior Vice President and Managing Director of Kvaerner Business Consulting. Initially he emphasized R&D strategy and M&A work (often in conjunction with major investment banking firms) while in recent years, he has focused on managing large, complex strategic R&D management, manufacturing optimization and compliance programs. Bills operating experience includes Manager of Operations for the Agricultural Chemicals Division of BASF in the 1970’s where his team supported the launch of Basagran, a highly successful herbicide. During the late 1990’s and early 2000’s he served as founder and CEO of researchproteins Inc, an early stage company that used a proprietary technology licensed from the University of Maryland to provide small quantities of proteins to the discovery research organizations of major pharmaceutical companies. He successfully raised capital from state of NJ agencies (won the NJEDA award for best business plan) and private investors and obtained contracts from 7 major pharmaceutical companies. He currently consults for large and small Pharma companies.

Major accomplishments include:

  • For a pharmaceutical and medical device company managed a supply chain management assignment called, “Worldwide Integrated Sourcing Plan”. A rigorous strategic, cost and engineering analysis that linked business strategy with manufacturing strategy was conducted to reach a consensus on the cost and benefits of change. As a result of this assignment, approximately 25% of the capacity was eliminated, but of greater importance, the operational improvements initiated served to dramatically lower cost. The value of the savings was publicly announced as $1.2 billion.
  • For Warner Lambert, assembled and managed a team of 40 professionals that successfully brought three pharmaceutical plants in Puerto Rico into cGMP. In this landmark assignment, we were retained as a result of an FDA consent decree that required that an independent organization certify that the facility was in compliance; after which time the FDA would re-audit the facility. If they agreed with our organization’s assessment, they would release our client from several onerous penalties. The program was successful and the FDA concurred that the plants were detailed substantially compliant. Our approach was to develop a detailed protocol that addressed each of the subparts of CFR 211 as well as cross-functional issues that have received increasing FDA scrutiny, such as change control. After auditing the facilities and identifying deficiencies, we worked with the client to develop remedial action plans, monitored progress of these plans and certified that the remedial action was successfully completed and the issue was eliminated and was now compliant.
  • For a major US ethical pharmaceutical & OTC drug company, we re-engineered QA operations including Quality Assurance, QC Laboratories and Validation. A new QA organization has been brought in and was faced with an organization that had a hostile adversarial relationship with operations and development caused by an extremely poor service level as measured by backlogs, turnaround time and retesting and a lack of precise, definitive standards for technology transfer and validation. Working with the organizations, and as a result of certain staffing changes, backlogs were eliminated, overtime was virtually eliminated and expectations were defined which greatly expedited the development process and resulted in substantial operational and cost improvements.

Bill received his B. S. from the Polytechnic Institute, Brooklyn NY and an MBA from Saint John’s University NY, NY.

Prof. Javed Iqbal

Prof. Javed Iqbal

Scientific Advisor

Prof. Javed Iqbal graduated from Delhi University, following which he worked as SERC post‐doctoral fellow in the group of Prof. Ian Fleming at Cambridge University. Subsequently he moved to Oxford University as a post‐doctoral fellow with Prof. Sir J.E. Baldwin and worked on penicillin biosynthesis, and then as a visiting fellow at the University of Montpellier, France.

After teaching for a year at the University of Montpellier, he returned to India and joined the faculty of the Indian Institute of Technology, Kanpur in the department of chemistry and became a professor there in 1990. He has also served as Director of the Regional Research Laboratory (CSIR), Trivandrum and as visiting professor at the University of Notre Dame, USA and the University of Okayama, Japan, and has taught chemistry at the New Mexico State University, Las Cruces, USA.

In the year 2000, he switched to industry, and moved to Dr. Reddy's Laboratories Ltd. (DRL) where he served as Senior Vice President, Distinguished Research Scientist and Global Head of Discovery Chemistry until 2007. He headed a research group of 150 scientists at DRL’s Hyderabad and Atlanta discovery research facilities. His discovery chemistry group at DRL was responsible for designing and synthesizing small molecules for therapeutic areas like Diabetes, Cancer, cardiovascular and anti-bacterial. Three of the drugs discovered by his group underwent Phase I clinical trials in Canada and the Ireland. He has published more than 200 research papers and has filed 105 patents in his area of research. He has mentored a number of research students including 35 doctoral and post-doctoral students. He has promoted start-up companies like Nutracryst Therapeutics (Co-crystal Technology), Zeephase Therapeutics (Zebra fish based technology), Cosmic Discoveries (Drug Discovery CRO).

He has served as an adviser to ICICI Venture, Mumbai, GLG, USA and Bill and Melinda Gates foundation, India. He was member of Council of Scientific and Industrial Research (CSIR) Society, headed by Prime Minister, Government of India. He is currently member of the committee on Drugs and Pharmaceuticals, Department of Science and Technology, Government of India.

Prof. Iqbal is a fellow of the Indian Academy of Science, Bangalore and Indian National Sciences Academy (INSA), New Delhi. He served as a Council Member of INSA and as member of the IUPAC committee on Chemistry and Drugs. He was conferred the Vigyan Gaurav Award by the Uttar Pradesh Government in 2006. He has also served as member of the International Advisory Committee of the journal Chem. Med. Chem. published by Wiley. He was member of regional committee for Asia and Pacific (RCAP) of International council of Science (ICSU), Kuala Lumpur, Malaysia and Chair, Science Planning Group on Epigenetics of RCAP-ICSU. He served as founder Director of Dr. Reddy’s Institute of Life Sciences in Hyderabad during 2007-2014. He is currently, Founder and Chairman of Cosmic Discoveries, Hyderabad and has strategic partnership on Drug Discovery and development with Sphaera Pharma INC., USA

Prof. ML Davies

Prof. ML Davies

Scientific Advisor

Huw M. L. Davies was born in Aberystwyth, Wales, UK. He received his B. Sc. degree from University College Cardiff, Wales and his Ph. D degree from the University of East Anglia. After a post-doctoral position at Princeton University, he joined the faculty at Wake Forest University. After being promoted to full professor he moved to the University at Buffalo, the State University of New York where he held the positions of UB Distinguished Professor and Larkin Professor of Organic Chemistry. In 2008 he moved to Emory University as the Asa Griggs Candler Professor of Organic Chemistry.

Professor Davies’ research emphasizes the development of new enantioselective synthetic methods and their applications in total synthesis and drug discovery. His program covers design of chiral catalysts, carbenoid chemistry, development of new synthetic methodology, total synthesis of biologically active natural products, and development of chiral therapeutic agents. Many research groups have used his chiral dirhodium catalysts and several of them are commercially available. The impact of his carbenoid chemistry was recently recognized as he was chosen to be the recipient of the 2013 eEROS Reagent of the Year Award.

A major current theme of his program is catalytic asymmetric C–H functionalization by means of rhodium-carbenoid induced C–H insertion. He is currently the Director of the NSF Phase II Center for Selective C-H Functionalization, which brings together 23 faculty members from 15 universities. Professor Davies is actively involved in the chemical community, having served as the Executive Officer of the 2003 National Organic Symposium, the 2005 Program Chair of the Gordon Conference on Heterocyclic Compounds, the 2005 Chair of the Organic Division of the American Chemical Society, and Co-Organizer of the ACS Organic Division yearly Assistant Professor Symposium at the Fall ACS meeting since 2006. Recent awards include the American Chemical Society Cope Scholar Award (2005), Fellow of the Royal Society of Chemistry (2007), Fellow of the American Chemical Society (2009), and Fellow of the American Association for the Advancement of Science (2012).